Image
Our lab is focused on understanding mechanisms of regulation of surface targets in bladder and prostate cancer. We work with pre-clinical models of these cancers (cell lines, xenografts, and organoids), leveraging whole genome CRISPR screening techniques to identify new therapies and novel combinations for testing in clinical trial. In parallel, we conduct correlative studies in patients undergoing neoadjuvant therapy, applying deep molecular profiling to define inter- and intra-tumoral heterogeneity and to map tumor evolution across treatment. Together, these efforts aim to bridge mechanistic discovery with biomarker development and next-generation therapeutic strategies.
